Program
QLC1401
A development code. Also written as “QLS1304 tablet+Fulvestrant or QLC1401” and “QLS1304 tablet+Fulvestrant,AI or QLC1401+CDK4/6i”.
Its studies are mostly in Breast Neoplasms, led by Qilu Pharmaceutical.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Qilu Pharmaceutical | 22 open or running | phase 2since Sep 7, 2025 | Sep 7, 2025 | Feb 2027phase 2 · NCT07173556 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Sep 7, 2025First study: phase 2 study in Advanced Breast CancerFirst studyNCT07173556 · 96 planned
- Nov 14, 2025Phase 2 study in Advanced ER+/HER2- Breast CancerNCT07235176 · 300 planned · China
Ahead
- Feb 2027Primary completion: phase 2 study in Advanced Breast CancerNCT07173556
- Nov 2, 2028Primary completion: phase 2 study in Advanced ER+/HER2- Breast CancerNCT07235176
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07235176Advanced ER+/HER2- Breast Cancer · China | 2 | Recruiting | Nov 2, 2028 | 300 |
| NCT07173556Advanced Breast Cancer | 2 | Not yet recruiting | Feb 2027 | 96 |
How it is read
Names in the registry
- “QLC1401”, 2 entries
- “QLS1304 tablet+Fulvestrant or QLC1401”, 1 entry
- “QLS1304 tablet+Fulvestrant,AI or QLC1401+CDK4/6i”, 1 entry
Codes read as this program: QLC1401.
Conditions, from the studies’ own filings
- Breast Neoplasms, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.